IP Library Granted Patent US 8,540,999
Granted Patent B2
US 8,540,999 · App. 10/931,260 · Granted Sep 24, 2013

Allergenic proteins and peptides from Japanese cedar pollen

Inventors: Irwin J. Griffith (North Reading, MA); Joanne Pollock (Arlington, MA); Julian F. Bond (Weymouth, MA); Richard D. Garman (Arlington, MA); Mei-Chang Kuo (Winchester, MA); Stephen P. Powers (Waltham, MA); Mark A. Exley (Brookline, MA); Xian Chen (North Chelmsford, MA); Ze'ev Shaked (Berkeley, CA)
Assignee: Merck Patent GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,540,999
App. No.
10/931,260
Granted
Sep 24, 2013
Kind
B2
Abstract

The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding naturally-occurring allergen or portion thereof but having reduced side effects. Methods of treatment or of diagnosis of sensitivity to Japanese cedar pollens in an individual and therapeutic compositions, and multipeptide formulations comprising one or more peptides of the invention are also provided.

Claims (2)

1. An isolated Japanese cedar pollen allergen produced in a host cell transformed with a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, or the coding region thereof, wherein the allergen is recombinantly produced is free of other cedar pollen ailergens and is non-glycosyl.

2. An isolated Japanese cedar pollen allergen, comprising the amino acid sequence of SEQ ID NO:2, or the mature portion thereof, wherein the allergen is recombinantly produced is free of other cedar pollen allergens and is non-glycosylated.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2006
From: HESKA CORPORATION
To: MERCK PATENT GMBH
Reel/Frame 018654/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2005
From: IMMULOGIC PHARMACEUTICAL CORPORATION
To: HESKA CORPORATION
Reel/Frame 016301/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2005
From: IMMULOGIC PHARMACEUTICAL CORPORATION
To: HESKA CORPORATION
Reel/Frame 016153/0837 →
Continuity (10)
Continuation 09240203 · Jan 29, 1999
Continuation 08467023 · Jun 6, 1995
Division 08350225 · Dec 6, 1994
Continuation In Part 08226248 · Apr 8, 1994
Continuation In Part 07975179 · Nov 12, 1992
Continuation In Part PCTUS9300139 · Jan 15, 1993
Continuation In Part 07938990 · Sep 1, 1992
Continuation In Part 07730452 · Jul 15, 1991
Continuation In Part 07729134 · Jul 12, 1991
Related Publication 20050152927A1 · Jul 14, 2005